October 25 is MDS World Awareness Day. We stand with everyone living with blood cancer — this month and every day.

Publications & Presentations

Advancing scientific understanding from research to real-world evidence.
Every study contributes to a deeper understanding of blood cancer and the potential for new treatment approaches. Through clinical trials, real-world evidence, investigator-sponsored research, and scientific collaboration, Geron is committed to generating evidence that may help advance science, inform clinical practice, and improve outcomes for people living with blood cancer.

Explore our scientific publications and presentations:

This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes only, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.

Journal articles

Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models

Journal of Clinical Medicine

September 23, 2026
Acute Myeloid Leukemia (AML)Preclinical Data

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

Blood Neoplasia

April 16, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Blood Cancer Journal

April 7, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

British Journal of Haematology

February 1, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Haematologica

January 22, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Nature Leukemia

January 12, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Blood Cancer Journal

December 31, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

Clinical and Translational Science

December 14, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Plain language summary of IMerge, a Phase 3 studyof imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Future Oncology

October 12, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Transfusion Independence Corresponds With Survival in Patients With Lower-Risk Myelodysplastic Syndrome: Real-World Evidence From United States Insurance Claims

Clinical Lymphoma, Myeloma and Leukemia

October 1, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Real-World Data

Imetelstat: A First-in-Class Telomerase Inhibitor for the Treatment of Patients With Lower-Risk Myelodysplastic Syndromes and Anemia

Online First

June 25, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Review

Low Proarrhythmic Risk of Imetelstat, a Novel Oligonucleotide Telomerase Inhibitor: A Translational Analysis

Clinical and Translational Science

January 21, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Conference presentations

Updated Analysis of Overall Survival With Imetelstat in Relapsed or Refractory Myelofibrosis from IMbark Versus Real-World Data, and Assessment of Real-World Treatment Patterns: Updated Post Hoc Analysis With Extended Follow Up

Society of Hematologic Oncology (SOHO) 2026

September 9, 2026
Myelofibrosis (MF)Real-World Data

Correlation Between IL-8 and TNF-Alpha and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus-Associated Kinase Inhibitor in the IMbark Trial

Society of Hematologic Oncology (SOHO) 2026

September 9, 2026
Myelofibrosis (MF)Clinical Data

Early Real-World Use and Hematologic Outcomes With Imetelstat in Patients With Myelodysplastic Syndromes: Insights From a United States Community Oncology Chart Review

Society of Hematologic Oncology (SOHO) 2026

September 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Real-World Data

Real-world Outcomes of Imetelstat: Interrogating Safety, Efficacy and Predictors of Response in Heavily Pretreated Lower-Risk MDS Patients

EHA 2026

June 12, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Updated analysis of overall survival with imetelstat in relapsed/refractory myelofibrosis versus real-world data, and assessment of real-world treatment patterns

ASCO 2026

June 1, 2026
Myelofibrosis (MF)Clinical Data

Updated protocol: IMproveMF, a Phase 1b trial of imetelstat+ruxolitinib in patients with intermediate-1/2 or high-risk myelofibrosis

ASCO 2026

June 1, 2026
Myelofibrosis (MF)Clinical Data

Long-Term Outcomes from Randomized, Double-Blind, Placebo-Controlled, Phase 3 IMerge Trial of Imetelstat for Lower-Risk Myelodysplastic Syndromes (LR-MDS)

ASH 2025

December 8, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Correlation between Interleukin (IL)-8 and Tumor Necrosis Factor (TNF)-Alpha Levels and Overall Survival in Patients (Pts) with Myelofibrosis (MF) Relapsed or Refractory (R/R) to a Janus-Associated Kinase Inhibitor (JAKi) Treated with Imetelstat (IME) in the IMbark Trial

ASH 2025

December 8, 2025
Myelofibrosis (MF)Clinical Data

IMproveMF: Phase 1b Trial of Imetelstat Plus Ruxolitinib in Patients with Intermediate-2 or High-Risk Myelofibrosis

ASH 2025

December 8, 2025
Myelofibrosis (MF)Clinical Data

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-based Therapy: Interim Analysis Results of the IMpress Study

ASH 2025

December 8, 2025
Acute Myeloid Leukemia (AML)Clinical Data

Correlation between Treatment-Emergent Cytopenias and Clinical Response with Imetelstat (IME) in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS): Analysis from the IMerge Trial

ASH 2025

December 8, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

IMpactMF, Randomized, Open-Label, Phase 3 Trial of Imetelstat Versus Best Available Therapy in Patients With Intermediate-2 or High-Risk Myelofibrosis Relapsed or Refractory to Janus Kinase Inhibitors

SOHO 2025

September 3, 2025
Myelofibrosis (MF)Clinical Data